Innately Fluorescent Tetravalent Cytotoxic Conjugate TetraF_HER2-vcMMAE Engages Aggregation-Dependent Endocytosis of HER2 for Enhanced Intracellular Drug Delivery.

ABSTRACT: Breast cancer is the most common malignancy in women, with approximately 20-30% of all diagnosed cases characterized by HER2 overexpression. Several HER2-targeted cytotoxic conjugates have been developed, but their efficacy is limited. One of the main obstacles restraining the effectiveness of HER2-specific cytotoxic conjugates is their low internalization, as HER2 is immobile mainly on the cell surface. Therefore, there is a need to develop novel HER2-selective cytotoxic conjugates that will overcome HER2 immovability and, by this, ensure efficient drug delivery into HER2-overexpressing cancer cells. Here, we present a novel system for generating high affinity, self-assembling, inherently fluorescent, and multivalent HER2 ligands. The developed HER2-specific ligands largely overcome the innate stability of HER2 in the plasma membrane by triggering clathrin-independent aggregation-dependent endocytosis of the receptor. To exploit the pro-endocytic potential of developed proteins, we constructed the tetravalent fluorescent cytotoxic conjugate TetraF_HER2-vcMMAE and demonstrated its high potency and selectivity against HER2+ breast cancer cells.

SUBMITTER: Porebska N 

PROVIDER: S-EPMC12257533 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature